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Abstract
CHD5 is frequently deleted in neuroblastoma and is a tumor suppressor gene. However, little is known about the role of
CHD5 other than it is homologous to chromatin remodeling ATPases. We found CHD5 mRNA was restricted to the brain; by
contrast, most remodeling ATPases were broadly expressed. CHD5 protein isolated from mouse brain was associated with
HDAC2, p66ß, MTA3 and RbAp46 in a megadalton complex. CHD5 protein was detected in several rat brain regions and
appeared to be enriched in neurons. CHD5 protein was predominantly nuclear in primary rat neurons and brain sections.
Microarray analysis revealed genes that were upregulated and downregulated when CHD5 was depleted from primary
neurons. CHD5 depletion altered expression of neuronal genes, transcription factors, and brain-specific subunits of the SWI/
SNF remodeling enzyme. Expression of gene sets linked to aging and Alzheimer’s disease were strongly altered by CHD5
depletion from primary neurons. Chromatin immunoprecipitation revealed CHD5 bound to these genes, suggesting the
regulation was direct. Together, these results indicate that CHD5 protein is found in a NuRD-like multi-protein complex.
CHD5 expression is restricted to the brain, unlike the closely related family members CHD3 and CHD4. CHD5 regulates
expression of neuronal genes, cell cycle genes and remodeling genes. CHD5 is linked to regulation of genes implicated in
aging and Alzheimer’s disease.
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Introduction
A role for CHD5 in cancer was first suggested by genetic
mapping studies in neuroblastomas [1,2]. Neuroblastomas fre-
quently harbor a deletion of the short arm of human chromosome
1, and the region shared by most deletions includes the CHD5
gene [1,3]. CHD5 was confirmed as the tumor suppressor in this
region, as depletion of CHD5 phenocopied the proliferative
defects found with deletions engineered in mice [2,4]. Depletion of
CHD5 reduced expression of another tumor suppressor, p19Arf,
suggesting that CHD5 mediates its tumor suppressive activity
through modulation of the p19arf/p53 pathway [4]. Subsequently,
CHD5 has been reported to be mutated, deleted or silenced in a
variety of human cancers including glioma, leukemia/lymphoma,
melanoma, breast, prostate, ovarian and gastric cancers
[5,6,7,8,9,10,11,12,13]. CHD5 expression has been suggested to
serve as a biomarker for positive outcomes in neuroblastoma
patients [14].
Chromodomain/helicase/DNA-binding domain (CHD) pro-
teins are found in eukaryotes from yeast through humans [15,16].
All CHD members contain two N-terminal chromodomains, a
helicase-like ATPase motif associated with nucleosome remodel-
ing, and a less well-defined C-terminal DNA binding domain. The
tandem chromodomains of CHD1 specifically recognize
H3K4Me3 and can facilitate the recruitment of post-transcrip-
tional initiation and splicing factors [17,18]. The human CHD
family is often divided by sequence homology: subfamily I (CHD1
and CHD2), subfamily II (CHD3 and CHD4) and subfamily III
(CHD6, CHD7, CHD8, CHD9); CHD5 has been grouped with
CHD 6–9 by some authors, and CHD 3–4 by others
[15,16,19,20]. Many remodeling ATPases are expressed ubiqui-
tously in the body plan. CHD5 is unusual in that its expression is
reported to be limited to the developing brain, adult brain and the
adrenal gland, suggesting a potential role in the development or
function of the neural system [21]. Deletion of a region of
chromosome 1 near CHD5 has been linked to intellectual
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development and function remains to be determined.
CHD3 and CHD4, also known as Mi-2alpha and Mi-2ß, are
found in multiprotein chromatin remodeling complexes named
NuRD [23,24,25,26,27,28]. In addition to the ATPase activity of
the CHD subunit, NuRD complexes include the histone
deacetylases HDAC1 and HDAC2. NuRD complexes include a
methyl CpG binding protein (MBD2 or MBD3), adapter proteins
(RbAp46 and/or RbAp48), p66, and a metastasis associated
protein (MTA1, 2 or 3).
CHD proteins have been demonstrated to regulate gene
expression, with CHD3and CHD4 being the best-studied examples
[24]. NuRD is often described as a transcriptional repressor, in part
because of the presence of histone deacetylase activity. However,
NuRD complex activity results in divergent outcomes for two target
genes in developing lymphocytes, mb-1 and CD4: NuRD inhibits
mb-1 transcription and activates CD4 transcription [29,30]. NuRD
is also an activator and repressor during blood development [31].
This behavior is reminiscent of the mammalian ISWI remodelers,
which are also often thought of as repressors, yet appear to possess
activationpotentialaswell[32,33,34].HowtheNuRDcomplexcan
differentially regulate gene transcription remains an open question
but it has been suggested to be an outcome of a regulated shift in the
composition of NuRD components or through the association with
other transcriptional regulators. Genome-wide analysis of Mi2
binding in D. melanogaster revealed association with regions that
appeared to be enhancers and promoters [35]. Less is known about
the potential chromatin remodeling and gene regulatory functions
of CHD5–CHD9. Whether CHD5 exists in a multi-protein
complex and functions to regulate gene expression in the brain
has not been reported.
Remodeling of chromatin structure is an important determinant
of cell fate decisions and function in the nervous system. In
particular, ATP-dependent remodeling has been shown to be
critical for the development of invertebrate and vertebrate nervous
systems [19,36,37]. The best-characterized example is SWI/SNF,
containing the BRG1 and BRM ATPases. The SWI/SNF
ATPases are ubiquitous, though the accessory proteins in the
complex are developmentally regulated. During the transition
from neural progenitor to post-mitotic neuron, BAF45a and
BAF53a are replaced by BAF45b and BAF53b to assemble the
brain-specific nBAF form of the SWI/SNF complex [38]. nBAF is
critical in neuron-specific function as BAF53b-deficient mice have
a defect in neuron dendrite outgrowth [39]. In addition to ATP-
dependent remodeling, HDAC-inhibitor studies revealed a role for
chromatin remodeling involving histone acetylation in synaptic
plasticity and learning behaviors [40,41]. Studies on HDAC2-
deficient mice implicated this particular deacetylase as a direct
negative regulator of learning and memory [42].
Here, we examine CHD5 in rodent brain and neurons. We
found CHD5 was present in a multiprotein NuRD-like complex.
CHD5 was expressed in several brain regions, and CHD5 was
found in neurons. Depletion of CHD5 from primary neurons
revealed genes that were activated and repressed by CHD5. The
targets included genes that were previously identified as important
for aging, Alzheimer’s disease, and neuronal development.
Binding of CHD5 to some of these target genes in intact cells
suggested they were directly regulated by CHD5.
Materials and Methods
Protein extracts from rat brain
Rat brain was dissected to separate the cortex, cerebellum,
hippocampus, brain stem and striatum. Nuclear extracts were
made from each rat brain section as described for mouse brain
nuclear extracts (Methods S1). 15 ug of nuclear extract from each
brain region was analyzed by SDS-PAGE, transferred to PVDF
membrane, and detected by immunoblotting using anti-HDAC-2
(Abcam ab7029), and reprobed with anti-CHD5 (HD5A-E Day
77). Animal approval for rats was from the NIA ACUC, protocol
ASP-289-MPM, and all experiments conform to the relevant
regulatory standards.
Staining of brain sections
CHD5 staining of the rat hippocampus was done as described
[43] using anti-CHD5 antibody (HD5A-A Day 77) or pre-immune
serum at 1:2000.
Staining of primary neurons
Rat primary neurons were harvested from E18 rats as described
[44]. Cells were plated on PEI coated coverslips and were grown in
Neural Basal Medium (+B27) for nine days in vitro (DIV). Cells were
fixed in 100% cold methanol for 15 minutes at 220uC, pre-incubated
with blocking buffer (2% nonfat powdered milk, 2% normal serum in
PBS) for 1 hour. Cells were incubated with primary antibodies diluted
1:1000 in blocking buffer for 72 hours at 4uC. Primary antibodies used
were: anti-CHD5 (HD5A-A Day 77) and anti Tuj1, mouse
monoclonal anti Beta-Tubulin isotype III (Sigma #T8660). Secondary
antibodies were Alexa 568 for Tuj1 and Alexa 488 for CHD5. Cells
w e r ec o u n t e r s t a i n e dw i t hD A P Ii nP B Sf o r1 0m i n u t e s .
Identification of proteins associated with CHD5
CHD5 antibody (HD5A-A Day 77) or pre-immune serum was
crosslinked to protein A beads as described [45]. Mouse brain
nuclear extract (12 mg) was diluted 1:4 in RIPA Buffer (50 mM
Tris, pH 7.5, 150 mM NaCl, 1% NP40, 0.5% sodium deoxycho-
late, 0.1% SDS), antibody/protein A beads were added and
incubated overnight at 4uC. The beads were pelleted, and washed
4 times with TX-100 Buffer [0.02 M Tris/HCl pH 8.0, 0.137 M
NaCl, 10% glyceol (v/v) and 1% Triton X-100 (v:v)] with protease
inhibitors. A final wash was performed with TE. The immuno-
precipitated proteins were eluted from the beads using 0.1 M
Glycine pH 2.5. The immunopurified proteins were analyzed by
SDS-PAGE on an 8% polyacrylamide gel. Protein bands were
visualized by silver staining (BioRad) or Colloidal Coomasie Blue
staining. Protein bands were excised from Coomasie-stained gels
and were sequenced (ProtTech Inc). Animal approval for mice was
from the NIA ACUC, protocol ASP-365-MJP-Mi, and all
experiments conform to the relevant regulatory standards.
Co-immunoprecipitation of proteins
Mouse brain nuclear extract was immunopurified as described
above except that these antibodies were crosslinked to the protein
A beads: anti-HDAC1 (Santa Cruz, sc-7872; Upstate, 06-720),
anti-HDAC2 (Abcam ab7029-50), anti-p66 Beta (Bethyl, A301-
281A). Other CHD5-interacting proteins were immunopurified
using the previously described protocol with these modifications:
the antibodies were not crosslinked to the protein A beads and the
nuclear extract was diluted into CoIP Buffer II (100 mM NaCl,
20 mM Hepes pH 7.5, 1 mM EDTA, 10% glycerol, 0.1% NP40).
Immunopurified proteins were analyzed by SDS-PAGE using 8%
Polyacrylamide gels. Immunoblot analysis was performed probing
for CHD5 using CHD5 antisera (HD5A-E Day 77).
Gel filtration analysis of CHD5
Mouse brain nuclear extract was dialyzed against PBS (MWCO
12–14,000, 6.4 mm diameter Spectrum Laboratories 132 676),
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0.2 mg was loaded onto a Sephadex 200 Column (Amersham) and
0.5 mL eluted fractions were collected and analyzed by SDS-
PAGE and western blot analysis. Sizing standards were run
according to the manufacturer’s instructions (Amersham High
Molecular Weight Gel Filtration Calibration Kit, 17-0441-01).
CHD5 protein depletion using lentiviral-delivered shRNA
CHD5 KD shRNA sequences (Table S5) were designed
according to the instructions for the pLKO.1 system (Addgene).
Control shRNA virus was plasmid 1864 from Addgene, as
described [46]. Virus was packaged using HEK-293T cells,
pLKO.1 vector with shRNA inserts for CHD5, psPAX2 and
pMD2.G. 48 hours after transfection of 293 cells, medium
containing virus was filtered (0.45 micron), then applied to
primary cortical neurons one day after the neurons were plated
(DIV 1) for 6 hours. Medium was removed, and replaced with
Neural Basal Medium, and the cells were cultured until RNA was
harvested at day 5, 9, or 12 (DIV 5, 9 or 12).
Validation of Microarray
RNA was harvested from primary cortical neurons infected with
the indicated lentivirus, as described above, at the indicated times.
RNA was isolated using RNAeasy Kit (Qiagen), cDNA was
synthesized using Iscript (BioRad). mRNA was quantified using
real time PCR and normalized to Actin (Actb), a housekeeping
gene; similar results were obtained normalizing to other
housekeeping genes such as Tbp [47] or Gapdh. Primer sequences
are listed in Table S5.
ChIP (chromatin immunoprecipitation)
ChIP was performed essentially as described [32,48,49,50,51],
with the following changes. Approximately 3610
6 primary cortical
neurons were cross-linked with 1% formaldehyde for 10 minutes,
then quenched with glycine. Cells were scraped into PBS, collected
by centrifugation, and lysed in 400 ul SDS Lysis Buffer (50 mM
Tris-HCl pH 8, 1% SDS, 10 mM EDTA). Nuclei were not
treated with MNase. Sonication was performed using a bath
sonicator (Bioruptor; Diagneode). Mouse brain ChIP was
performed as described [32,52]. CHD5 ChIP was performed
using CHD5 antisera on day 9 (HD5A-A Day 77). Rat and mouse
primer sequences are listed in Table S5.
Results and Discussion
CHD5 mRNA is preferentially found in brain
CHD5 expression was initially reported to be limited to brain,
though others have found CHD5 expression elsewhere, so there is
some controversy about sites of CHD5 expression [4,7,9,13,21].
We examined CHD5 mRNA in mouse and human organs, and
found that CHD5 mRNA was abundant in brain, approximately 7
fold lower in mouse testes, and 2–4 orders of magnitude lower in
all other tested mouse and human organs (Figure 1a,b). Little if
any CHD5 mRNA was found in the neuroblastoma cell line SH-
SY5Y; this is a negative control, as neuroblastoma cells generally
do not express the neuroblastoma tumor suppressor gene CHD5.
By contrast, for the same mouse mRNA samples, the ratio of the
highest to lowest expression for CHD4, BRG1 and SNF2H (three
other remodeling ATPases) was about 5 fold, indicating they were
broadly expressed (Figure 1b). We place CHD5 along with CHD4
in the Mi2 group of remodeling ATPases by sequence homology
(see below), thus the contrast in expression was specific to CHD5,
not a property of the Mi2 family. CHD5 mRNA was detected at
E15.5, when the brain is mostly neurons with relatively few glial
cells, and increased after birth and to adulthood (Fig. 1c). RNA
encoding other remodeling enzymes was also detected, including
CHD3 and CHD4, sequence homologs of CHD5 (Fig. 1c). Again,
the expression of CHD5 was very different than the expression of
the paralogs CHD3 and CHD4.
CHD5 is a nuclear protein found in neurons
Remodeling ATPases are grouped by homology into subfam-
ilies. Based upon sequence identity and domain structure, CHD5
is a member of the Mi2 group, along with the paralogs CHD3 and
CHD4 (Figure S1). CHD5 is most homologous to CHD4, with
70% amino acid identity and identical domain structure (Paired
PHD domains, paired chromodomains, SNF-2-like ATPase
domain). By comparison, CHD5 shares only 18% identity with
SNF2H, an ISWI ATPase, and 18% identity with BRG1, a
SWI2/SNF2 ATPase. We made antisera targeted to CHD5 N-
terminal fragments (Figure S1b) that specifically recognize CHD5,
and used these antisera to test for CHD5 in brain. We found
CHD5 protein was expressed in various regions of rodent brain
(Figure 2a). By contrast, CHD5 protein was not detected in HeLa
(epitheliod), SH-SY5Y (neuroblastoma), NT2 (embryonal carci-
noma), and EL4 (T cell) cell lines, consistent with the lack of
CHD5 mRNA in these cells (Figure 2a and data not shown).
CHD5 staining was not detected in SH-SY5Y cells, a human
neuroblastoma line; following transfection with a human CHD5
cDNA, nuclear staining was readily apparent in these cells
(Figure 2). This suggested that our antisera were specific for
CHD5; we used SH-SY5Y as a negative control because they a
cell line with a neuronal phenotype that lack the neuroblastoma
suppressor CHD5. CHD5 protein expression was examined in
rodent brain sections. CHD5 protein was readily detected at
regions rich in neuronal cell bodies, and was not detected in glial
cell rich regions, suggesting CHD5 was a neuronal protein found
in cell nuclei (Figure 3a), consistent with a recent report [14].
These signals were not detected when CHD5 primary antibody
was omitted from the staining procedure (data not shown).
Staining of primary rat neurons confirmed CHD5 was predom-
inantly a nuclear protein in neurons (Figure 3b).
Of course, it is not possible to prove a negative proposition. We
were not able to detect CHD5 mRNA or protein outside of brain
and perhaps testes at levels higher than in our neuroblastoma
negative control. It is nonetheless possible that CHD5 below our
detection limit has some important functional role in these cells. In
addition, we did not test all possible cell types at developmental
stages, so there may be other cell types that express CHD5.
Examination of published reports of CHD5 expression outside
brain, revealed that several measured mRNA and did not detect
the protein [4,7,9], another reports CHD5 is a cytoplasmic protein
[13] and another reports a CHD5-specific antibody detects CHD5
in HeLa cells [53].
CHD5 is found in a NuRD-like complex
We asked whether CHD5 was associated with other proteins.
Human CHD3 and CHD4 form NuRD-like complexes [24],
while Drosophila Mi2 proteins have also been found as free
proteins and in complexes without NuRD components [reviewed
in 54]. We considered that CHD5 could be in NuRD-like
complexes, or perhaps in non-NuRD complexes like the fly
homolog. We immunopurified CHD5 from mouse brain nuclear
extracts, isolated gel slices, and identified proteins using mass
spectrometry. Little, if any, CHD5 was found in the cytoplasmic
fraction, consistent with our staining results. Our immunopurifica-
tion appeared to be specific for CHD5, as sequencing of the band
at the expected size for CHD5 revealed the presence of peptides
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either CHD3 or CHD4 that were absent from CHD5 (Table S1a).
Note that CHD3 and CHD4 are identical in size to CHD5, thus
cannot be distinguished by electrophoretic mobility. We identified
MTA3, p66ß and HDAC1/2 as proteins associated with CHD5
(Figure 4a and Table S1). These components or homologs have
been found in NuRD complexes along with the ATPases CHD3
and CHD4 [25,26,27,28], suggesting CHD5 was in a NuRD-like
complex.
We used co-immunoprecipitation experiments to further define
CHD5-interacting proteins. We confirmed the interaction of
MTA3, p66ß, and HDAC2 with CHD5 (Figure 4b). We also
detected a strong interaction with RbAp46 (Figure 4b). A weak
interaction was found with MBD3; it is not clear whether the lower
signal reflects MBD3 abundance, stability of interaction with
MBD3 or antibody efficiency. We noted HDAC1 was detected at
lower levels than HDAC2 (Figure 4b and Table S1b), suggesting
that CHD5 was preferentially interacting with HDAC2. Immu-
noblotting with HDAC1 instead of CHD5 confirmed HDAC1 was
immunoprecipitated with HDAC1 antisera, but not by CHD5
antisera (Figure 4c). Immunoblotting with HDAC2 confirmed that
CHD5, p66ß and HDAC2 antisera immunoprecipitated HDAC2.
Both HDAC1 and HDAC2 were readily detected in nuclear
extracts from mouse brain and HeLa cells (Figure 4c).
Figure 1. CHD5 expression is restricted to brain. A,B) RNA from
human (A) or mouse (B) organs was used to synthesize cDNA, which
was then quantified by real-time PCR. Signal was normalized to the
expression of the housekeeping gene Actin. The bars indicate the
averages and standard deviations of three experiments. A) SH-SY5Y
indicates the human neuroblastoma cell line SH-SY5Y; neuroblastoma
cells do not express the tumor suppressor CHD5. B) expression for each
remodeling enzyme was normalized to the expression level in mouse
brain; thus, a value of 1 means the expression for that enzyme in that
tissue is the same as brain. CHD5 was not detected in mouse Th1 and
Th2 cells (primary naı ¨ve CD4+ T lymphocytes differentiated in culture to
the Th1 or Th2 fate; data not shown). C) RNA obtained from dissected
mouse brain (brain at E15.5, cortex at P16, and adult cortex) as well as
commercial mouse brain RNA was used to synthesize cDNA, which was
then quantified by real-time PCR for each of the indicated remodeling
enzyme ATPases. Signal was normalized to the expression of the
housekeeping gene Actin. Mouse brain at E15.5 is essentially cortical
neurons. The bars indicate the averages and standard deviations of
three experiments.
doi:10.1371/journal.pone.0024515.g001
Figure 2. CHD5 protein is expressed in several brain regions. A)
The indicated regions were dissected from rat brain. Nuclear extracts
were made from rat brain and HeLa cells. Equal amounts of protein
were loaded in each lane. CHD5 was detected by immunoblotting with
HD5A-E day 77. The same filter was reprobed for HDAC2 as a loading
control. B–E) CHD5 antibody specificity. SH-SY5Y neuroblastoma cells
were transfected with human CHD5 cDNA (D, E) or control (B, C) using
lipofectamine2000. Cells were fixed with methanol 220uC 15 minutes,
visualized by phase contrast (B, D) or were stained for CHD5 protein
(primary is 1:1000 CHD5 antisera HD5A-A day 77, secondary is Alexa 488
anti-rabbit).
doi:10.1371/journal.pone.0024515.g002
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affinity, or alternatively cells expressing CHD5 might contain
more HDAC2 than HDAC1. We transfected CHD5 cDNA into
HeLa cells, which contain HDAC1, HDAC2, CHD3, and CHD4
[26,27], but lack CHD5 (Figure 2a). CHD5 could interact with
both HDAC1 and HDAC2 in these cells, as found for CHD4
(Figure S2). This also indicates the HDAC1 antibody is capable of
identifying HDAC1/CHD5 complexes, when present. Others
have found that neurons preferentially contain HDAC2 instead of
HDAC1 [42,55], and this may account for the specificity of the
CHD5-HDAC2 interaction we observed in neurons and brain.
We fractionated nuclear proteins using size-exclusion chroma-
tography, to ask whether CHD5 protein also existed as monomers.
CHD5 migration was approximately megadalton, and little or no
CHD5 was detected at the expected size for monomeric or dimeric
CHD5 (Figure 4c), suggesting CHD5 was predominantly present
in a large complex similar in size to NuRD and SWI/SNF ATP-
dependent remodeling enzymes. HDAC2 and p66ß co-migrated
with CHD5, consistent with the proteins being present in a
NuRD-like complex (Figure 4c). We did not detect smaller
complexes, as found for Mi2 proteins in flies.
CHD5 depletion alters neuronal expression of genes
implicated in aging, Alzheimers’, and neuronal function
We hypothesized that CHD5 might regulate neuronal gene
expression. To deplete primary neurons of CHD5, we constructed
lentiviral vectors to express shRNA targeting CHD5. We
Figure 3. CHD5 protein is a nuclear protein in rodent brain and
cultured neurons. A) Rat brain sections were prepared, stained with
CHD5 antisera HD5A-A day 77, and protein was visualized using
immunohistochemistry. B) Neurons harvested from E18 rats were
grown on coverslips, and stained for CHD5 (Green; Antisera HD5A-A day
77) and a neuronal marker (Red- Tuj1), and counterstained for DNA
(Blue-DAPI). Individual and merged panels are shown.
doi:10.1371/journal.pone.0024515.g003
Figure 4. CHD5 protein is found in a NuRD-like complex in
mouse brain. A) Proteins were purified from mouse brain nuclear
extract using CHD5 antisera HD5A-A day 77 or control IgG crosslinked
to Protein A beads. Proteins were analyzed by SDS-PAGE and detected
by silver stain. B) Mouse brain nuclear extracts were immunoprecipi-
tated using the antisera indicated below, analyzed by SDS-PAGE,
transferred, and detected by immunoblotting using CHD5 antisera.
Note different CHD5 antisera were used for IP (HD5A-A day 77) and for
immunoblotting (HD5A-E day 77). C) Mouse brain nuclear extracts were
immunoprecipitated using the antisera indicated below, analyzed by
SDS-PAGE, transferred, and detected by immunoblotting using HDAC1
or HDAC2 antisera. Brain indicates mouse brain nuclear extract; HeLa
indicates HeLa nuclear extract. D) Mouse brain nuclear extracts were
size-fractionated using gel filtration. Size of fractions was estimated by
calibrating the column with standards. Fractions were analyzed by SDS-
PAGE, transferred, and detected by immunoblotting with the indicated
antisera (for CHD5, antisera HD5A-E day 77 was used). The input nuclear
extract (NE) is shown as a positive control.
doi:10.1371/journal.pone.0024515.g004
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expressed in primary rat neurons (Figure 5a); shRNA that reduced
CHD5 mRNA also reduced CHD5 protein. We identified CHD5-
dependent gene expression in primary neurons using microarray
analysis (described in detail in Methods S1); primary data were
deposited in GEO (GSE27620). We found the expression of
several hundred genes was augmented or diminished following
depletion of CHD5 protein; approximately similar numbers of
genes were affected in each direction (Figure 5b). Pathways from
the MSigDB database of the BROAD institute of MIT were
queried for regulation by CHD5; these gene sets come from many
cell types and sources [56]. At both day 9 and day 12 of
differentiation, the most strongly downregulated gene sets were
‘‘AGEING_BRAIN_UP’’, a gene set identified from aging human
brain, [57] and ‘‘STEMCELL_NEURAL_UP’’; ‘‘ALZHEI-
MERS_DISEASE_UP’’, a gene set identified in human brains
of Alzheimer’s patients [58] was also strongly downregulated,
while ‘‘ALZHEIMERS_INCIPIENT_UP’’ [58] was downregu-
lated less strongly (Table S2). The ‘‘AGEING_BRAIN_DN’’ gene
set [57] was upregulated at the same times; thus, CHD5 had
opposite effects on genes that were upregulated and downregu-
lated in the human brain during aging. At day 5, ‘‘RETT_DN’’
[59] and ‘‘NGFPATHWAY’’ were also upregulated at day 5. To
our knowledge, CHD5 had not previously linked to aging or
Alzheimer’s disease.
Among GO term gene sets, defects in expression of neuronal
gene sets were prominent (Table S3). ‘‘NEURON FATE
COMMITMENT’’ was significantly upregulated at day 12,
‘‘BEHAVIORAL FEAR RESPONSE’’ was downregulated at
days 9 and 12; ‘‘NEGATIVE REGULATION OF NEURON
DIFFERENTION’’ was upregulated at days 9 and 12, ‘‘SYN-
APSE ORGANIZATION AND BIOGENESIS’’ was upregulated
at day 12, ‘‘NEURON PROJECTION’’ was upregulated at days
5 and 9, while ‘‘NEURITE DEVELOPMENT’’, ‘‘FOREBRAIN
DEVELOPMENT’’, and ‘‘DENDRITE’’ were upregulated at day
9. Cell cycle defects were also evident: ‘‘CELL DIVISION’’ was
significantly upregulated at day 12; ‘‘REGULATION OF
PROGRESSION THROUGH CELL CYCLE’’ was downregu-
lated days 5, 9, and 12; ‘‘CYCLIN DEPENDENT PROTEIN
KINASE ACTIVITY’’ was downregulated at days 5 and 12.
CHD5 had not been identified as part of any of these pathways
prior to our work.
We validated selected expression changes using independent
biological samples. Targets were considered validated by us when
the initial microarray result (performed as a timecourse, in
triplicate) was reproduced in at least 3 independent replicate
experiments (also performed as timecourses in triplicate); any
target that did not replicate in the experiment performed using a
different shRNA reagent was considered a potential off-target
result. We tested genes previously implicated in Alzheimer’s
disease through gene set enrichment analysis, and confirmed that
App and ApoE were downregulated by a reduction in CHD5,
suggesting CHD5 was activating their expression (Figure 6 and
Table S4). CHD5 mRNA was also downregulated by the
knockdown, while the highly homologous CHD3 and CHD4
were unaffected (data not shown). We next validated genes with
known neuronal function including Vip, Npy, Maoa, Dlx1, Nrxn1,
Fmr1, Dlx1, Nefl, and Nefm (Figure 6 and Table S4). Reduction
in CHD5 expression reduced the amount of mRNA for these
genes. For other neuronal genes (L1cam, Gabrd, Ampd3) CHD5
functioned as a repressor (Table S4). We confirmed CHD5
activation of expression of the transcription factors Nfia and Id2
(Figure 6 and Table S4). Nfia was previously identified as an
activator of Ndrg2 expression in brain [60]; we verified Ndrg2
expression was reduced by CHD5 inhibition (Table S4), which
may be mediated by loss of Nfia. Finally, we examined chromatin
remodeling enzymes and other regulators, confirming expression
increased for the SWI/SNF components Baf45b/Neud4, Baf53b/
Actl6b and BAF 60a/Smarcd1, the histone methyltransferases
Suv39h1 and Suv420h2 and the micro-RNA processing enzyme
Dicer (Figure 6 and Table S4). Baf45b and Baf53b are both brain
specific components of the SWI/SNF complex varaint nBAF,
which is also restricted to brain [36,38,39]. The functions of nBAF
include development of neurons after neuronal precursor
formation and dendrite formation. We found the GO term
‘‘DENDRITE’’ was upregulated at day 9 following inhibition of
CHD5, consistent with our finding that CHD inhibition increased
expression of the nBAF components Baf45b and Baf53b.
We note that the effects of CHD5 depletion are most prominent
at different times for different genes. We do not yet understand
Figure 5. Inhibition of CHD5 protein expression in primary rat
neurons. A) Neurons from E18 rats were cultured, infected with the
indicated CHD5 lentivirus (1–8) or control lentivirus (Control shRNA,
GFP) on day 1, protein was harvested at day 5, analyzed by SDS-PAGE,
transferred, and immunoblotted with antisera recognizing CHD5
(HD5A-E day 77) or HSP90 (a loading control). Mouse brain nuclear
extract is shown as a positive control. B) Neurons from E18 rats were
cultured, infected with CHD5 lentivirus 1 or control lentivirus on day 1,
and mRNA was harvested at day 5, 9 and 12. cDNA was synthesized,
then quantified using Illumina microarrays. The number of genes that
were upregulated (green) and downregulated (red) in a statistically
significant manner was counted at days 5, 9, and 12. ‘‘All genes’’ is the
sum of genes upregulated and dowregulated by inhibition of CHD5
protein. Microarray data are deposited in GEO (GSE27620).
doi:10.1371/journal.pone.0024515.g005
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expression at the earliest time tested, while for other genes such as
Vip and Baf45b, the effect of CHD5 depletion is not detected until
later. We hypothesize that in these cases, CHD5 might be working
with a pathway that is turned on after several days of culture. For
example, CHD5 might activate Vip through a transcription factor
that is repressed or inactive at day 5, and expressed/activated
later, in which case CHD5 would have no detectable effect until
the transcription factor recruiting CHD5 was functional.
CHD5 binds target genes, suggesting direct regulation
As noted above, changes in gene expression caused by reduction
in CHD5 protein could be the direct result of CHD5 function on
these target genes. Alternatively, CHD5 function could be indirect,
for example CHD5 might regulate expression of a regulator of a
target gene. To distinguish these possibilities, we performed ChIP
for CHD5 on cultured rat neurons. We found CHD5 binding to
the CHD5 targets Nfia, Vip, App, Baf45b, and Ddit4 (Figure 7a).
CHD5 binding was 2 to 10 fold greater than control IP at these
target loci, while CHD5 binding was at background (similar to
control IP) at other loci such as downstream of the Fos promoter
(+13.4k). There was no simple correlation between CHD5 binding
and H3K9,14 acetylation or H3K27me3 (Figure 7b and data not
shown), suggesting it was unlikely these positive and negative
marks served to recruit CHD5. We investigated sequences flanking
the DDIT4 promoter to test our ChIP specificity; we found little if
any CHD5 signal at several nearby loci (Figure 7c). We extended
our ChIP to mouse brain; using an organ obtained from an
animal, rather than cultured cells, we found CHD5 binding to the
CHD5 promoter using 2 different primer sets (Figure 7d). Again,
CHD5 signal was absent at flanking regions, confirming the
specificity of our CHD5 ChIP in a second species.
CHD5 has been identified as a tumor suppressor for
neuroblastoma. However, little is known about the function of
CHD5. We found CHD5 was a nuclear protein predominantly
found in neurons. We found CHD5 was in a megadalton, NuRD-
like complex containing HDAC2, p66ß, MTA3, RbAb46 and
MBD3. CHD5 was present early in development and in adult
brain, and CHD5 was expressed in several brain regions, implying
CHD5 may play a broad role in brain development or function.
CHD5 appears to regulate gene expression, as inhibition of CHD5
protein expression alters mRNA amounts of many genes. To our
Figure 6. Depletion of CHD5 protein alters gene expression in primary rat neurons. Rat neurons were harvested and plated (D0), infected
with CHD5 or control lentivirus 24 hours later (D1) and mRNA was harvested Day 5, 9, and 12. cDNA was synthesized, and quantified using
quantitative PCR. mRNA amounts were normalized to the housekeeping gene TBP. ‘‘KD’’ indicates infection with CHD5 lentivirus, ‘‘Con’’ indicates
infection with control lentivirus. Symbols indicate average values from 3 plates, while error bars indicate standard deviations. The absolute expression
of these genes is quite different, so they are plotted to different scales.
doi:10.1371/journal.pone.0024515.g006
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neurons. A previous report of gene regulation by CHD5 was
performed in fibroblasts, and did not determine whether CHD5
bound the target genes [4]. The regulation we observed may be
direct in some cases, as CHD5 binding was found at a number of
these target genes at promoters and distal sites. Using microarrays
and pathway analysis, we found CHD5 regulated genes that were
previously found to change expression in response to aging or
Alzheimer’s disease, suggesting CHD5 may play a broader role in
human disease than currently recognized.
Supporting Information
Figure S1 CHD5 motifs and sequence homology. A) The
human protein sequences of the indicated ATPases were aligned
using MacVector (Accelrys Inc.). The Mi2, SWI/SNF, ISWI,
CHD1/2, and CHD6-9 subfamilies are indicated. CHD5 and Mi2
subfamily are marked in red. B) Motifs from representative
ATPase family members were identified using PROSITE [61].
The ATPases and domains are drawn to the same scale; increasing
length corresponds to more amino acids. The N terminus of each
protein is at the left. PhD domains are in red, chromo domains are
in blue, ATPase domains are in green, and other domains not
found in the Mi2 subfamily are shown in black. Ab1 indicates
region targeted by antisera HD5A-E, and Ab2 indicates region
targeted by antisera HD5A-A.
(EPS)
Figure S2 CHD5 is capable of binding HDAC1. HeLa
cells were transfected with human CHD5 cDNA (shown) or
control (not shown). Extracts were immunoprecipitated with the
indicated antisera, analyzed by SDS-PAGE, transferred, and
detecting by immunoblotting with the indicated antisera. Note
that CHD5 IP does not enrich for CHD4, suggesting these
proteins are not associated, and CHD5 antisera does not cross-
react with CHD4.
(EPS)
Table S1 Peptide sequence from CHD5 and associated
proteins. Table S1a- CHD5 Peptides. Table S1b- HDAC2
Figure 7. CHD5 protein binds to target genes in primary rat neurons and mouse brain. Neurons from rats were cultured; neurons and
brain were crosslinked with formaldehyde, and analyzed by ChIP-Q-PCR with the indicated antibodies (for CHD5, antisera HD5A-A day 77 was used)
as described in the methods. Fos +13.4k locus is one measure of background for CHD5 ChIP; we have not found CHD5 binding to this region. Another
measure of background is ChIP with control IgG; the mean+standard deviation for all loci was approximately equal to 0.05 in rat primary neurons,
similar to the signal we see at Fos +13.4k, and 0.02 in mouse brain. The gene name and the distance from the TSS are listed below. Data are shown as
the averages and standard deviations of three experiments performed with independent preparations of primary rat neurons and mouse brains. A)
CHD5 binding, primary rat neurons. B) H3K9,14 acetylation, (a mark associated with some active chromatin), primary rat neurons. C) CHD5 binding,
primary rat neurons. D) CHD5 binding, mouse brain.
doi:10.1371/journal.pone.0024515.g007
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peptides.
(DOCX)
Table S2 Gene sets altered in a statistically significant
manner by CHD5 inhibition. The columns ‘‘Pathway Name’’
and ‘‘Annotation’’ list gene sets from the molecular signature
database. Z scores for changes in the gene set are listed in the
following columns. ‘‘D12KD_D12C’’ compares gene set expression
after treatment with CHD5 shRNA lentivirus to contol, at day 12.
Negative Z scores indicate expression of the gene sets are reduced,
and thus CHD5 is formally an activator, while positive Z scores
indicate expression of the gene sets are increased, and thus CHD5
formally represses them. ‘‘D9KD_D9C’’ and ‘‘D5KD_D5C’’
measure the effect of CHD5 depletion at earlier times.
‘‘D12C_D5C’’ and ‘‘D9C_D5C’’ compare the change in gene set
expression in control cells at day 12 and day 9 relative to day 5.
(XLS)
Table S3 GO term gene sets altered in a statistically
significant manner by CHD5 inhibition. The columns
‘‘Gene Ontology Term’’ and ‘‘Annotation’’ list gene sets from the
molecular signature database. Z scores for changes in the gene set are
listed in the following columns. ‘‘D12KD_D12C’’ compares gene set
expression after treatment with CHD5 shRNA lentivirus to contol, at
day 12. Negative Z scores indicate expression of the gene sets are
reduced, and thus CHD5 is formally an activator, while positive Z
scores indicate expression of the gene sets are increased, and thus
CHD5 formally represses them. ‘‘D9KD_D9C’’ and ‘‘D5KD_D5C’’
measure the effect of CHD5 depletion at earlier times. ‘‘D12C_D5C’’
and ‘‘D9C_D5C’’ compare the change in gene set expression in
control cells at day 12 and day 9 relative to day 5.
(XLS)
Table S4 Summary of CHD5 targets validated by Q-RT-
PCR. The column ‘‘Target of CHD5’’ lists genes identified as
CHD5 targets using microarray analysis. The column ‘‘CHD5
Function’’ lists the result validated in at least 3 independent
experiments. ‘‘Activator’’ indicates expression was reduced follow-
ing CHD5 depletion for at least one time window, ‘‘Repressor’’
indicates expression was increased following depletion, while
Activator/Repressor indicates both, at different times. ‘‘CHD5
Binding’’ indicates measurement by ChIP; Yes indicates binding
above control IP and control locus. ‘‘Region(s) indicate where
binding was (or was not) observed. ‘‘Gene Sets’’ indicates, for the
gen in that row, the gene sets from Table S2 this gene is found.
(XLS)
Table S5 Sequences. 5A) Primers for measuring mRNA
amounts using Q-RT-PCR. 5B) Mouse primers. 5C) Rat primers.
5D) Primers for detecting proteins in rat chromatin using ChIP.
5E) Sequences and names for pLKO.1 lentivirus shRNA
constructs. 5F) Primers for expressing hCHD5 fragments to raise
antisera.
(DOCX)
Methods S1 Production of CHD5 antisera, character-
ization of CHD5 antisera specificity, isolation of mouse
brain nuclear extracts, measurement of mRNA from
mouse and human organs, Illumina BeadChip analysis,
and Pathway analysis are described. Additional references
are provided.
(DOCX)
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